These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 15133497)

  • 21. Glutaredoxin is a direct target of oncogenic jun.
    Goller ME; Iacovoni JS; Vogt PK; Kruse U
    Oncogene; 1998 Jun; 16(22):2945-8. PubMed ID: 9671415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells.
    Wu M; Min C; Wang X; Yu Z; Kirsch KH; Trackman PC; Sonenshein GE
    Cancer Res; 2007 Jul; 67(13):6278-85. PubMed ID: 17616686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional profile of Ki-Ras-induced transformation of thyroid cells.
    Visconti R; Federico A; Coppola V; Pentimalli F; Berlingieri MT; Pallante P; Kruhoffer M; Orntoft TF; Fusco A
    Cancer Invest; 2007 Jun; 25(4):256-66. PubMed ID: 17612936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-regulation of overexpressed sp1 protein in human fibrosarcoma cell lines inhibits tumor formation.
    Lou Z; O'Reilly S; Liang H; Maher VM; Sleight SD; McCormick JJ
    Cancer Res; 2005 Feb; 65(3):1007-17. PubMed ID: 15705902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KLF8 transcription factor participates in oncogenic transformation.
    Wang X; Zhao J
    Oncogene; 2007 Jan; 26(3):456-61. PubMed ID: 16832343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional co-factor CDCA4 participates in the regulation of JUN oncogene expression.
    Tategu M; Nakagawa H; Hayashi R; Yoshida K
    Biochimie; 2008 Oct; 90(10):1515-22. PubMed ID: 18572021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. c-Jun induces apoptosis of starved BM2 monoblasts by activating cyclin A-CDK2.
    Vanhara P; Bryja V; Horváth V; Kozubík A; Hampl A; Smarda J
    Biochem Biophys Res Commun; 2007 Feb; 353(1):92-7. PubMed ID: 17173865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased keratinocyte proliferation by JUN-dependent expression of PTN and SDF-1 in fibroblasts.
    Florin L; Maas-Szabowski N; Werner S; Szabowski A; Angel P
    J Cell Sci; 2005 May; 118(Pt 9):1981-9. PubMed ID: 15840658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer.
    Cai C; Hsieh CL; Shemshedini L
    Mol Cancer Res; 2007 Jul; 5(7):725-35. PubMed ID: 17634427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
    Kim YH; Girard L; Giacomini CP; Wang P; Hernandez-Boussard T; Tibshirani R; Minna JD; Pollack JR
    Oncogene; 2006 Jan; 25(1):130-8. PubMed ID: 16116477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adrenomedullin promotes cell cycle transit and up-regulates cyclin D1 protein level in human glioblastoma cells through the activation of c-Jun/JNK/AP-1 signal transduction pathway.
    Ouafik L; Berenguer-Daize C; Berthois Y
    Cell Signal; 2009 Apr; 21(4):597-608. PubMed ID: 19166930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines.
    Park SW; Sung MW; Heo DS; Inoue H; Shim SH; Kim KH
    Oncogene; 2005 Oct; 24(44):6689-98. PubMed ID: 16007171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells.
    Hommura F; Katabami M; Leaner VD; Donninger H; Sumter TF; Resar LM; Birrer MJ
    Mol Cancer Res; 2004 May; 2(5):305-14. PubMed ID: 15192124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside).
    Miura Y; Kainuma M; Jiang H; Velasco H; Vogt PK; Hakomori S
    Proc Natl Acad Sci U S A; 2004 Nov; 101(46):16204-9. PubMed ID: 15534203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Juggling jun.
    Weitzman JB
    Nat Genet; 2002 Feb; 30(2):128-9. PubMed ID: 11818953
    [No Abstract]   [Full Text] [Related]  

  • 36. Establishment and characterization of clonal cell lines derived from a fibrosarcoma of the H2-K/V-JUN transgenic mouse. A model of H2-K/V-JUN mediated tumorigenesis.
    Hatina J; Hájková L; Peychl J; Rudolf E; Fínek J; Cervinka M; Reischig J
    Tumour Biol; 2003; 24(4):176-84. PubMed ID: 14654711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular biology of deregulated gene expression in transformed C3H/10T1/2 mouse embryo cell lines induced by specific insoluble carcinogenic nickel compounds.
    Landolph JR; Verma A; Ramnath J; Clemens F
    Environ Health Perspect; 2002 Oct; 110 Suppl 5(Suppl 5):845-50. PubMed ID: 12426144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Charles S. Mott Prize. Jun: a transcription factor becomes oncogenic.
    Vogt PK
    Cancer; 1992 May; 69(10):2610-4. PubMed ID: 1568185
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro reversion of transformed phenotype in mouse C3H/10T1/2 cells.
    Paquette B; Wagner R; Little J
    Int J Oncol; 1996 Apr; 8(4):727-34. PubMed ID: 21544420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogene at last--c-Jun promotes liver cancer in mice.
    Maeda S; Karin M
    Cancer Cell; 2003 Feb; 3(2):102-4. PubMed ID: 12620404
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.